Pharosgr
Not stated on page, GR · Founded 2002 · 406 employees on LinkedIn · 2 known investors
PharOS is a pharmaceutical company that develops and launches generic and branded medicines, distributing affordable, high-quality pharmaceutical products to customers across more than 119 countries worldwide.
Also known as PharOS · PharOS Pharmaceuticals
Investors · 2
Company profile
researched Aug 2026PharOS is a privately owned pharmaceutical company that develops, manufactures and supplies generic and value added pharmaceutical products. Its portfolio comprises more than 113 products developed or under development, of which 64 have been launched, and it holds over 10,308 marketing authorizations worldwide. The company states a presence in more than 119 countries and a client base of more than 490 customers.
The organization describes itself as multi-disciplinary, covering the full span of pharmaceutical product development from active pharmaceutical ingredient (API) sourcing through to market release. Stated functional areas include product development; chemistry, manufacturing and controls; business development; contract manufacturing; regulatory affairs; pharmacovigilance; batch release; and supply chain management. Its stated mission is to bring customers' products to market among the first after patent expiry and to remain in the market last.
Business model
PharOS develops, registers, manufactures and supplies generic and value added pharmaceutical products, serving more than 490 clients across more than 119 countries. Alongside its own product development and registration activity, the company lists contract manufacturing and regulatory/pharmacovigilance capabilities among its service areas.
Traction
More than 113 products developed or under development, 64 products launched, over 10,308 marketing authorizations worldwide, presence in more than 119 countries and more than 490 clients.
▸Full profile — market position, technology, go-to-market, geography
Market position
The company positions its workforce of more than 413 professionals and its multi-disciplinary in-house coverage of the full development-to-market-release chain as its core competitive advantage, together with a "first to launch, last to exit" approach to post-patent-expiry generics.
Technology
Capabilities span the pharmaceutical development chain, including API sourcing, chemistry, manufacturing and controls, regulatory affairs, pharmacovigilance, batch release and supply chain management.
Go-to-market
Pharmaceutical companies and distributors that license, register or source generic and value added medicines; the company reports more than 490 clients.
Geography
Based in Greece, with a stated commercial presence in more than 119 countries and products registered, under registration, or launched across those markets.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
▸Research sources · 1
primary sources listed
- Pharosgrpharosgr.gr · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Pharosgr do?
- PharOS is a privately owned Greek pharmaceutical company developing, manufacturing and supplying generics and value added products.
- Who are Pharosgr's investors?
- Pharosgr's investors include Metavallon VC, Viessmann Generations Group.
- Where is Pharosgr headquartered?
- Pharosgr is headquartered in Not stated on page, GR.